Rapport sur la santé dans le monde

Chapter 5


Documents connexes

  • Bailey C. Using knowledge management to make health systems work. Bulletin of the World Health Organization, 2003, 81:777.
  • Msellati P, Juillet-Amari A, Prudhomme J, Akribi HA, Coulibaly-Traore D, Souville M et al. Socio-economic and health characteristics of HIV-infected patients seeking care in relation to access to the Drug Access Initiative and to antiretroviral treatment in Cote d’Ivoire. AIDS, 2003, 17(Suppl.8):S63–S68.
  • Katz MH, Schwarcz SK, Kellogg TA, Klausner JD, Dilley JW, Gibson S et al. Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. American Journal of Public Health, 2002, 92:388–394.
  • Blower S, Schwartz EJ, Mills J. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies and imperfect vaccines. AIDS Reviews, 2003, 5:113–125.
  • Moatti JP, Souteyrand Y. HIV/AIDS social and behavioural research: past advances and thoughts about the future. Social Science and Medicine, 2000, 50:1519–1532.
  • Poppen PJ, Reisen CA. Perception of risk and sexual self-protective behavior: a methodological critique. AIDS Education and Prevention, 1997, 9:373–390.
  • Bajos N. Social factors and the process of risk construction in HIV sexual transmission. AIDS Care, 1997, 9:227–237.
  • Schoepf B. International AIDS research in anthropology: taking a critical perspective on the crisis. Annual Review of Anthropology, 2001, 30:335–361.
  • De Cock K, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E et al. Prevention of motherto- child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA, 2000, 283:1175–1182.
  • Cooper ER, Charurat M, Mofenson L, Hanson IC, Pitt J, Diaz C et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. AIDS, 2002, 29:484–494.
  • Dorenbaum A, Cunningham CK, Gelber RD, Culnane M, Mofenson L, Britto P et al. Twodose intrapartum/newborn nevirapine and standard ARV therapy to reduce perinatal HIV transmission: a randomized trial. JAMA, 2002, 288:189–198.
  • Mofenson LM, Munderi P. Safety of antiretroviral prophylaxis of perinatal transmission for HIV-infected pregnant women and their infants. AIDS, 2002, 30:200–215.
  • Dabis F, Ekpini ER. HIV-1/AIDS and maternal and child health in Africa. Lancet, 2002, 359:2097–2104.
  • The public health bene. ts of microbicides: model projections. New York, Rockefeller Foundation, 2002.
  • Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK et al. Replicationincompetent adenoviral vaccine vector elicits effective anti-immunode. ciency-virus immunity. Nature, 2002, 415:331–335.
  • Klausner RD, Fauci AS, Corey L, Nabel GJ, Gayle H, Berkley S et al. Medicine. The need for a global HIV vaccine enterprise. Science, 2003, 300:2036–2039.
  • Adherence to HIV treatment. Genève, Organisation mondiale de la Santé, 2003 (Département VIH/SIDA, internal technical brief, non publié).
  • Lanièce I, Ciss M, Desclaux A, Diop K, Mbodj F, Ndiaye B et al. Adherence to HAART and its principal determinants in a cohort of Senegalese adults. AIDS, 2003, 17(Suppl. 3): S103–S108.
  • Farmer P, Leandre F, Mukherjee JS, Claude M, Nevil P, Smith-Fawzi MC et al. Communitybased approaches to HIV treatment in resource-poor settings. Lancet, 2001, 358:404–409.
  • Katzenstein D, Laga M, Moatti JP. The evaluation of the HIV/AIDS Drug Access Initiatives in Côte d’Ivoire, Senegal and Uganda: how access to antiretroviral treatment can become feasible in Africa. AIDS, 2003, 17(Suppl. 3):S1–S4.
  • Spire B, Duran S, Souville M, Leport C, Raf. F, Moatti JP et al. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Social Science and Medicine, 2002, 54:1481–1496.
  • Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M et al. Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, 2001, 358:1322–1327. Erratum 358:2088.
  • Fliers E, Sauerwein HP, Romijn JA, Reiss P, van der Valk M, Kalsbeek A et al. HIV-associated adipose redistribution syndrome as a selective autonomic neuropathy. Lancet, 2003, 362:1758–1760.
  • Reiss P. How bad is HAART for the heart? AIDS, 2003, 17:2529–2531.
  • Valdez H, Lederman MM, Woolley I, Walker CJ, Vernon LT, Hise A et al. Human immunode. ciency virus 1 protease inhibitors in clinical practice: predictors of virological outcome. Archives of Internal Medicine, 1999, 159:1771–1776.
  • Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB et al. Long-term followup studies con. rm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nature Medicine, 2003, 9:727–728.
  • Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB et al. A trial of three regimens to prevent tuberculosis in Ugandan adults infected with the human immunode. ciency virus. New England Journal of Medicine, 1997, 337:801–808.
  • L’accès aux traitements du VIH/SIDA en Côte d’Ivoire. Paris, Agence Nationale de Recherches sur le Sida, 2001.
  • L’initiative sénégalaise d’accès aux traitements antirétroviraux. Analyses économiques, sociales, comportementales et médicales. Paris, Agence Nationale de Recherches sur le Sida, 2002.
  • Loevinsohn M, Gillespie S. An ‘HIV/AIDS lens’ to guide agricultural and food policy in Africa. Washington, D.C., International Food Policy Research Institute, 2003.
  • Moatti JP, Coriat B, Souteyrand Y, Barnett T, Dumoulin J, Flori YA. Economics of AIDS and access to HIV/AIDS care in developing countries. Issues and challenges. Paris, Agence Nationale de Recherches sur le Sida, 2003.
  • Disentangling HIV and AIDS stigma in Ethiopia, Tanzania, and Zambia. Washington, D.C., International Center for Research on Women, 2003.
  • Parker R, Aggleton P. HIV and AIDS-related stigma and discrimination: a conceptual framework and implications for action. Social Science and Medicine, 2003, 57:13–24.
  • Déclaration d’engagement sur le VIH/SIDA. New York, Nations Unies, 2001 (Session extraordinaire de l’Assemblée générale des Nations Unies sur le VIH/SIDA, 25–27 juin 2001).